PRF1

Chr 10AR

perforin 1

Also known as: HPLH2, P1, PFP

This gene encodes a protein with structural similarities to complement component C9 that is important in immunity. This protein forms membrane pores that allow the release of granzymes and subsequent cytolysis of target cells. Whether pore formation occurs in the plasma membrane of target cells or in an endosomal membrane inside target cells is subject to debate. Mutations in this gene are associated with a variety of human disease including diabetes, multiple sclerosis, lymphomas, autoimmune lymphoproliferative syndrome (ALPS), aplastic anemia, and familial hemophagocytic lymphohistiocytosis type 2 (FHL2), a rare and lethal autosomal recessive disorder of early childhood. [provided by RefSeq, Aug 2017]

Primary Disease Associations & Inheritance

Aplastic anemiaMIM #609135
Hemophagocytic lymphohistiocytosis, familial, 2MIM #603553
AR
Lymphoma, non-HodgkinMIM #605027
0
ClinVar variants
0
Pathogenic / LP
0.00
pLI score
8
Active trials
Clinical SummaryPRF1
Population Constraint (gnomAD)
Low constraint (pLI 0.00) — loss-of-function variants are relatively tolerated in the population.
💊
Clinical Trials
8 active or recruiting trials — potential therapeutic options may be available
Some data sources returned errors (1)

clinvarCount: Error: NCBI fetch failed: 429 https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esearch.fcgi

Population Genetics & Constraint

gnomAD v4 — loss-of-function & missense intolerance

Tolerant — LoF & missense variants common in population
LoF Constraint?LOEUF (Loss-of-function Observed/Expected Upper bound Fraction) is the upper bound of the 90% CI for LoF OE — the preferred gnomAD v4 metric. Lower = more intolerant to LoF. LOEUF < 0.35 = highly constrained.
1.19LOEUF
pLI 0.000
Z-score 1.05
OE 0.70 (0.431.19)
Tolerant

Highly tolerant — LoF variants common in population

Missense Constraint?Missense Z-score: standard deviations fewer missense variants observed vs. expected. Z > 3.09 (p < 0.001) = gene does not tolerate missense variation. OE missense < 0.6 is also considered constrained.
0.02Z-score
OE missense 1.00 (0.911.09)
351 obs / 351.9 exp
Tolerant

Mild missense constraint

Observed / Expected Ratios?Shaded band = 90% confidence interval. Vertical tick = point estimate. Grey threshold line = gnomAD constraint cutoff for that variant class.
LoF OE?Ratio of observed to expected LoF variants. Upper CI bound (LOEUF) ≤ 0.35 = strong LoF constraint signal.0.70 (0.431.19)
00.351.4
Missense OE?Ratio of observed to expected missense variants. OE ≤ 0.6 = fewer missense variants than expected by chance.1.00 (0.911.09)
00.61.4
Synonymous OE?Control metric — synonymous variants are largely neutral and expected near OE = 1.0. Significant deviation may indicate annotation issues.1.04
01.21.6
LoF obs/exp: 10 / 14.3Missense obs/exp: 351 / 351.9Syn Z: -0.39

ClinVar Variant Classifications

0 submitted variants in ClinVar

Protein Context — Lollipop Plot

PRF1 · protein map & ClinVar variants

Showing all ClinVar variants across the protein. Search a specific variant to highlight its position.

OMIM — Genotype-Phenotype Relationships

1 OMIM entry

PERFORIN 1; PRF1
MIM #170280 · *

Aplastic anemia

MIM #609135

Molecular basis of disorder known

Hemophagocytic lymphohistiocytosis, familial, 2

MIM #603553

Molecular basis of disorder known

Autosomal recessive

Lymphoma, non-Hodgkin

MIM #605027

Molecular basis of disorder known

Clinical Literature
Landmark / reviewRecent case evidence

Clinical Trials

Active and recruiting trials from ClinicalTrials.gov

Myelodysplastic Syndrome

Study of an Innovative Therapy Using CAR-T Cells Targeting IL-1RAP in Patients With High-Risk Myelodysplastic Syndromes (MDS

NOT YET RECRUITING
NCT07455500Phase NAUniversity Hospital, GrenobleStarted 2026-05
Bone marrow and blood sampling
EndometriosisAdenomyosis

Pain in Endometriosis And the Relation to Lifestyle

RECRUITING
NCT06332560Phase NARadboud University Medical CenterStarted 2024-10-04
Anti-inflammatory diet (DI)Cognitive behavioral therapy (CBT)
Transplantation InfectionKidney Diseases

Molecular Biological and Moleculargenetic Monitoring of Therapy After Kidney Transplantation

RECRUITING
NCT01515605Odense University HospitalStarted 2011-01-01
Malnutrition PregnancyMalnutrition in ChildrenMalnutrition (Calorie)

Early Life Malnutrition, Environmental Enteric Dysfunction and Microbiome Trajectories

RECRUITING
NCT07195006University of ZimbabweStarted 2025-01-27
Malnutrition in pregnancy as exposurePoor WASH living conditions as exposure
Early Breast CancerTriple Negative Breast Cancer

Trial for Treatment of High Risk BC With Two Sequences of Neoadjuvant Chemotherapy With Pembrolizumab

NOT YET RECRUITING
NCT06371807Phase PHASE2Fundacao ChampalimaudStarted 2024-07
Pembrolizumab injection
Bladder Cancer

Antitumor T Cell Responses in Patients With Bladder Cancer

NOT YET RECRUITING
NCT06334406Centre Hospitalier Universitaire de BesanconStarted 2024-04-02
Biological samples
Diabetes MellitusPancreas TransplantationAllograft Rejection

The Norwegian Pancreas Transplantation (PTx) Study

ENROLLING BY INVITATION
NCT01957696Oslo University HospitalStarted 2013-09
Post-Acute COVID-19 Syndrome

A Study of Apabetalone in Subjects With Long -COVID

RECRUITING
NCT06590324Phase PHASE2, PHASE3Resverlogix CorpStarted 2025-04-15
Apabetalone